NCT02726997 2025-12-18Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur)M.D. Anderson Cancer CenterPhase 1/2 Active not recruiting18 enrolled